Abstracts tagged "opioids and pain"

Abstract Number: 2231 • 2017 ACR/ARHP Annual Meeting
MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain
Raini Dutta¹, Mary Lunzer², Jennifer L. Auger³, Eyup Akgün², Philip Porthoghese² and Bryce A. Binstadt³, ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, ³Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN
Background/Purpose: The pain that accompanies rheumatoid arthritis and other chronic inflammatory conditions is difficult to manage. Although opioids provide potent analgesia, chronic opioid use is…
Abstract Number: 2992 • 2017 ACR/ARHP Annual Meeting
Curbing the Opioid Epidemic: Predictors of Opioid Use in Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Rui Xiao², Andrea M. Knight³, David D. Sherry¹, Pamela F. Weiss⁴ and Jeffrey S. Gerber⁵, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Despite the lack of evidence to support the use of opioids in the treatment of adult fibromyalgia syndrome, approximately 30% of patients receive an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].